Tg Therapeutics (TGTX) Equity Ratio (2011 - 2026)

Tg Therapeutics' Equity Ratio history runs 16 years deep, the most recent figure standing at 0.38 for Q1 2026.

• In Q1 2026, Equity Ratio rose 5.56% year-over-year to 0.38; the TTM figure through Mar 2026 stood at 0.38 (up 5.56% YoY), while the FY2025 annual figure was 0.61, up 58.34% from the prior year.
• Equity Ratio was 0.38 for Q1 2026 at Tg Therapeutics, down from 0.61 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.61 in Q4 2025 to a low of 0.14 in Q1 2023.
• Historically, Equity Ratio has averaged 0.42 across 5 years, with a median of 0.43 in 2024.
• The sharpest annual moves came in 2023 and 2024: Equity Ratio sank 75.28% in 2023, then surged 208.54% in 2024.
• A 5-year view of Equity Ratio shows it stood at 0.3 in 2022, then soared by 60.9% to 0.49 in 2023, then dropped by 20.96% to 0.38 in 2024, then surged by 58.34% to 0.61 in 2025, then slumped by 37.42% to 0.38 in 2026.
• The last three Equity Ratio figures came in at 0.38 (Q1 2026), 0.61 (Q4 2025), and 0.59 (Q3 2025), per Business Quant data.